This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

NovoPen® 6 & NovoPen Echo® Plus: Simply smart.

The smart insulin pens NovoPen® 6 & NovoPen Echo® Plus are built for reliable insulin dose recording.4–6 Using individual injection data means you can have informed discussions with your patients living with diabetes.3,4,7
Dose Check: basal insulin dosing guidance app

You can use the Dose Check app to extend support to your patients wherever they are.7 Dose Check guides the patient to adjust their insulin doses to reach their target fasting blood glucose and provides daily dose guidance to help them manage their type 2 diabetes.7–9
Mallya®, a smart cap for pen injectors

You can turn your patients’ disposable insulin pens into smart pens, simply by attaching Mallya® on the dose selector of their current pen.10,11 This smart device automatically captures injection data (dose, date, and time), enabling you and your patients to easily track their daily injections.10,11

1.

Allen NA, et al. J Clin Transl Endocrinol 2016;7:1–6.

2.

Kerr D, et al. Endocr Pract 2022;28(8):811–821.

3.

Klonoff DC, et al. J Diabetes Sci Technol 2018;12(3):551-553.

4.

NovoPen® 6 & NovoPen Echo® Plus Design Specification / Verification Report (Data on File).

5.

Adolfsson P, et al. Diabetes Technol Ther 2020;22(10):709–718.

6.

Kalergis M, et al. Can J Diabetes 2006;30(3):241–247

7.

Dose Check 2.x Device Description.

8.

Dose Check Evidence-Based Titration Plans Reference Document (Data on file).

9.

Clinical Evaluation Report for iSage Rx and Dose Check Software Application (CER-001) Ver.17 (Data on File).

10.

Mallya® Design Specification / Verification Report (Data on File)

11.

Mallya® Summative Study (Data on File)

 

NovoPen® 6 and NovoPen Echo® Plus are CE-marked medical devices. Notified body 0123.
NovoPen® 6 and NovoPen Echo® Plus are certified against the EU Medical Device Directive (MDD) 93/42/EEC.
NovoPen® 6 and NovoPen Echo® Plus are available in a number of countries with additional launches planned in the near future. Timeframes will vary according to device, insulin brand and unique market regulations.


Dose Check is CE marked. Notified body 2862. Dose Check is certified against the EU Medical Device Regulation (MDR) 2017/745.
Manufacturer: Amalgam Rx, Inc. 1007 N. Orange St, Ste. 400, Wilmington, DE 19801, USA
Authorized Representative: Medical Device Safety Service GmbH, Schiffgraben 41, 30175 Hannover, Germany.
Dose Check is available in a number of countries and additional launches are planned in the near future. Time frames will vary according to device, insulin brand and unique market regulations.
Dose guidance apps and the information contained in these materials are not intended as a substitute for professional medical advice.

Mallya® is an electronic device for the wireless collection and transfer of data of doses administered by an injection pen. Mallya® is a regulated healthcare product and carries the CE mark. Mallya® is CE marked as a Class 1 medical device in accordance with the EU Medical Device Regulation (MDR), 2017/745.
Legal manufacturer: Biocorp Production – 453 541 054 RCS Clermont-Ferrand – La Bechade ZI La Lavaur, 63500 Issoire, France. Read instructions carefully.
Mallya® is available in Japan and additional launches are planned in the near future. Time frames will vary according to device, insulin brand, and unique market regulations.


The information contained on this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is suitable for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness, or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.


HQ24MLY00030, June 2024